Mapping the effect of drugs on ACE2 as a novel target site for COVID-19 therapy
H.F. Hetta, K. Muhammad, A.M. Algammal, H. Ramadan, M.S. Abdel-Rahman, M. Mabrok, G. Koneru, A.A. Elkady, G. El-Saber Batiha, Y. Waheed, N. Munawar, H.S.M. Farghaly Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA. nmunawar@uaeu.ac.ae
Angiotensin converting enzyme 2 (ACE2) has potentially conflicting roles in health and disease. COVID-19 coronavirus binds to human cells via ACE2 receptor, which is expressed on almost all body organs. Boosting the ACE2 receptor levels on heart and lung cells may provide more cellular enter to virus thereby worsening the infection. Therefore, among the drug targets, ACE2 is suggested as a vital target of COVID-19 therapy. This hypothesis is based on the protective role of the drugs acting on ACE2. Therefore, this review discusses the impact and challenges of using ACE2 as a target in the current therapy of COVID-19.
Free PDF Download
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
H.F. Hetta, K. Muhammad, A.M. Algammal, H. Ramadan, M.S. Abdel-Rahman, M. Mabrok, G. Koneru, A.A. Elkady, G. El-Saber Batiha, Y. Waheed, N. Munawar, H.S.M. Farghaly
Mapping the effect of drugs on ACE2 as a novel target site for COVID-19 therapy
Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 10
Pages: 3923-3932
DOI: 10.26355/eurrev_202105_25963